Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Express Scripts to add Zepbound to National Preferred Formulary
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
GMM Pfaudler US completes acquisition of MixPro
The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana
Subscribe To Our Newsletter & Stay Updated
